Clinical Trials

MK-9999-01C/LIGHTBEAM-U01 - LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

Link : https://www.clinicaltrials.gov/ct2/show/NCT06941272
Status : span class="RECRUITINGgreen">RECRUITING
Population : Children and teens (between 1 month to 17 years old) with Rhabdomyosarcoma (RMS)
Description : HER3-DXd (also known as MK-1022 or patritumab deruxtecan)
PI : D. Morgenstern
Centers Opened : SickKids
Phase : I/II
IIST/Pharma : Pharma